Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CET

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:14p MYOKARDIA : Announces Receipt of Milestone Payment from Sanofi for DCM Candidate..
12/02 SANOFI : gains two places in the Access to Medicine Index
12/01 MYMETICS : NetworkNewsBreaks – Mymetics (MYMX) Shares Skyrocket on Agreeme..
12/01 SANOFI : Receives FDA Approval of Soliqua 100/33 for the Treatment of Adults wit..
12/01 MYMETICS CORPORATION (OTCMKTS : MYMX) Files An 8-K Entry into a Material Definit..
11/29 NOVO NORDISK A/S : reports Tresiba insulin achieves target in study
11/29 SANOFI : to expand its Miskolc plant with an investment of 5 billion forints
11/29 SANOFI : FDA approval for Sanofi's Soliqua to treat type 2 Diabetes
11/28 SANOFI : Disclosure of trading in own shares
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 Approvals Of Novel Molecules Set To Plunge In 2016
12/02 MyoKardia earns $25M milestone from Sanofi for MYK-491 IND
12/01 ALLERGAN : Low Enough To Like, Or Valeant-Lite?
11/30 Latest Setback Sends Amicus Back To The Drawing Board
11/30 Warren Buffett's Only 3 Dividend Stocks With 4%+ Yields
Advertisement
Financials (€)
Sales 2016 36 745 M
EBIT 2016 9 372 M
Net income 2016 5 436 M
Debt 2016 5 746 M
Yield 2016 3,99%
P/E ratio 2016 16,46
P/E ratio 2017 14,96
EV / Sales 2016 2,80x
EV / Sales 2017 2,82x
Capitalization 97 094 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,1 €
Spread / Average Target 7,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.20%103 510
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results